Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company focused on innovative cancer treatments, has announced the issuance of 333 restricted stock units (RSUs) to a newly-hired employee. The grant, effective as of July 31, 2025, is part of the company's 2022 Inducement Stock Incentive Plan. These RSUs will vest over three years, with equal portions vesting on each anniversary of the grant date, contingent upon continued employment. Additionally, the RSUs will fully vest should the employee be terminated without cause, or resign for good reason, within a year following a change in control event. This move is in accordance with Nasdaq Listing Rule 5635(c)(4).
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。